Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC).
Authors
Marwan Fakih
City of Hope National Comprehensive Cancer Center, Duarte, CA;
Marwan Fakih , Jaideep Singh Sandhu , Dean Lim , Sierra Li , Chongkai Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04362839
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 110)
DOI
10.1200/JCO.2023.41.4_suppl.110
Abstract #
110
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY).
First Author: Markus H. Moehler
Poster
2023 ASCO Annual Meeting
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
First Author: Heinz-Josef Lenz
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
First Author: Christopher Williams